Immuron hails record monthly sales of Travelan

–News Direct–

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travelan. For August, the company registered Australian sales amounting to A$1.18 million, representing a staggering 7,984% increase compared to A$14,581 in August 2022. The monumental sales boost partially mirrors the clearance of a three-month backlog of orders, which had accumulated during a period awaiting Good Manufacturing Practice (GMP) clearance from the TGA.

Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers diarrhea,

Travelan is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers diarrhea. In Australia, Travelan is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers Diarrhea. In the U.S., Travelan is sold as a dietary supplement for digestive tract protection.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

View source version on

Immuron Ltd

comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Boston New Times  journalist was involved in the writing and production of this article.

Written by